|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapyстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus- Авторы: Gushchin Vladimir A., Tsyganova Elena V., Ogarkova Darya A., Adgamov Ruslan R., Shcheblyakov Dmitry V., Glukhoedova Nataliia V., Zhilenkova Aleksandra S., Kolotii Alexey G., Zaitsev Roman D., Logunov Denis Y., Gintsburg Alexander L., Mazus Alexey I.
- Журнал: EClinicalMedicine
- Номер: 46
- Год издания: 2022
- Издательство: Elsevier
- Местоположение издательства: United States
- DOI: 10.1016/j.eclinm.2022.101360
- Аннотация: Abstract: SummaryBackgroundHIV-infection is known to aggravate the course of many infectious diseases, including COVID-19. International guidance recommends vaccination of HIV+ individuals against SARS-CoV-2. There is a paucity of data on epidemiological efficacy assessment of COVID-19 vaccines among HIV+. This paper provides a preliminary assessment of Sputnik V vaccine effectiveness in HIV+ patients on antiretroviral therapy (ART).MethodsWe performed a retrospective cohort study to assess the effectiveness of the standard Sputnik V vaccination regimen in 24,423 HIV+ Moscow residents during spring - summer 2021, that included dominance of delta variant, with estimation of hospitalization and severe illness rates in vaccinated and unvaccinated patients. Data were extracted from the Moscow anti-COVID-19 vaccination and COVID-19 incidence Registries.FindingsThe data obtained indicate that Sputnik V epidemiological efficiency in the entire cohort of HIV+ on ART was 76·33%; in HIV+ with CD4+ ≥ 350 cells/µl, vaccine efficiency was 79·42%, avoiding hospitalization in 90·12% cases and protecting from the development of moderate or severe disease in 97·06%. For delta variant in this group the efficiency was 65·35%, avoiding the need for hospitalization in 75·77% cases and protecting from the development of moderate or severe disease in 93·05% of patients. There was a trend, although not statistically significant, of declining vaccine efficiency in immune-compromised individuals (CD4+ < 350 cells/µl).InterpretationThe study suggested epidemiological efficiency of immunization with Sputnik V in HIV+ ART-treated patients for the original and delta SARS-CoV-2 variants.
- Добавил в систему: Гущин Владимир Алексеевич